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Background—Genome wide association studies identified several single nucleotide
polymorphisms (SNPs) associated with prevalent coronary heart disease (CHD) but less is known
of associations with incident CHD. The association of thirteen published CHD SNPs was
examined in five ancestry groups of four large US prospective cohorts.
Methods and Results—The analyses included incident coronary events over 9.1 to 15.7
average follow-up times in up to 26,617 white individuals (6,626 events), 8,018 African
Americans (914 events), 1,903 Hispanics (113 events), 3,669 American Indians (595 events) and
885 Asian/Pacific Islanders (66 events). We used Cox proportional hazards models (with additive
mode of inheritance) adjusted for age, sex and ancestry (as needed). Nine loci were statistically
associated with incident CHD events in whites: 9p21 (rs10757278, p=4.7 × 10−41), 16q23.1
(rs2549513, p=0.0004), 6p24.1 (rs499818, p=0.0002), 2q36.3 (rs2943634, p=6.7 × 10−6),
MTHFDIL (rs6922269, p=5.1 × 10−10), APOE (rs429358, p=2.7 × 10−18), ZNF627 (rs4804611,
p=5.0 × 10−8), CXCL12 (rs501120, p=1.4 × 10−6) and LPL (rs268, p=2.7 × 10−17). The 9p21
region showed significant between-study heterogeneity, with larger effects in individuals aged 55
years or younger and in women. Inclusion of coronary revascularization procedures among the
incident CHD events introduced heterogeneity. The SNPs were not associated with CHD in
African Americans and associations varied in other US minorities.
Conclusions—Prospective analyses of white individuals replicated several reported cross-
sectional CHD-SNP associations.
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Recent genome wide association studies (GWAS) identified several single nucleotide
polymorphisms (SNPs) in genes or regions associated with coronary heart disease (CHD).
Most were retrospective case-control comparisons and little is known about the contribution
of these genetic variants to the risk of incident CHD in the general population.
One of the loci most studied for CHD is the 9p21 region near the CDKN2A-2B genes. This
58 kb region, in high linkage disequilibrium (LD) in individuals of European ancestry,
overlaps a large noncoding RNA (antisense noncoding RNA in the INK locus – ANRIL),
which may contribute to atherosclerosis through regulatory function on the CDKN2A-2B
genes1. In addition to clinical CHD, variants in the 9p21 region (i.e., rs10757274 and
rs2383206) have shown associations with coronary artery calcification2, 3, premature
atherosclerosis2, ischemic stroke 4, heart failure 5, peripheral artery disease6, abdominal
aortic aneurysm and intracranial aneurysm 7 in white populations. Helgadottir et al reported
early age of onset effects for CHD for this locus8. A recent meta-analysis of 22 studies
including 35,872 cases and 95,837 controls, mostly whites, also suggested a larger effect
(magnitude of association) of 9p21 variants in studies with earlier age of onset of clinical
CHD9. Generalization of the genetic effects of this locus to populations of Asian ancestry
was also observed in the latter meta-analysis.
A limited number of prospective studies of CHD have replicated the associations of the
9p21 region with incident CHD in white individuals, such as participants of the
Atherosclerosis Risk in Communities (ARIC) study2. However, the associations did not
replicate in studies of African Americans, including the ARIC study participants 2, 10
although it must be noted that the number of observations was suboptimal in several of these
studies 3. To our knowledge, a meta-analysis of the association of the 9p21 locus with
incident CHD in other US minorities has not been done. We also note that additional loci for
CHD have been recently described 11-13(CELSR2/PSRC1, MTHFD1L, MIA3 among others);
these associations have not been replicated in US minorities.
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The Population Architecture using Genomics and Epidemiology (PAGE) Study enables a
comprehensive analysis of the association of previously validated CHD variants with
incident CHD in data from multiple prospective cohort studies, diverse cultural, ancestral
and socio-economic settings. We examined whether CHD-related SNPs are associated with
incident CHD in individuals of European ancestry in PAGE, and evaluated whether these
SNPs are associated with incident CHD in US minorities, specifically in individuals self-
identified as African American, American Indian, Hispanic and Asian/Pacific Islanders.
Methods
Population and definition of CHD events
The PAGE Study includes four large ongoing NIH-funded population based studies or
consortia: EAGLE (Epidemiologic Architecture for Genes Linked to Environment, based on
three National Health and Nutrition Examination Surveys 14, NHANES), MEC (the
Multiethnic Cohort study15), WHI (Women’s Health Initiative16), and CALiCo (Causal
Variants Across the Life Course, a consortium of 5 cohort studies: Atherosclerosis Risk in
Communities (ARIC)17, Coronary Artery Risk in Young Adults [CARDIA]18,
Cardiovascular Health Study [CHS]19, Hispanic Community Health Study/Study of Latinos
[HCHS/SOL], and Strong Heart Study [SHS] 20, 21). This report is based on prospective data
on incident CHD from the ARIC, CHS, SHS and WHI studies. Fatal and non-fatal incident
CHD events were defined as acute myocardial infarction (MI), fatal CHD, ECG diagnosis of
MI (except in the WHI), and/or documented coronary revascularization procedures, based
on record abstraction and confirmed by a panel of physician reviewers. Prevalent cases of
CHD at the respective baseline visits were excluded.
The design of the parent studies has been previously described. Briefly, the ARIC study is a
multi-center prospective investigation of atherosclerotic disease in a bi-racial population
(white and African Americans).17 ARIC recruited 15,792 individuals aged 45-64 years from
four communities for a baseline examination in 1987-1989, with follow-up examinations in
approximate 3-year intervals, during 1990-1992, 1993-1995, and 1996-1998. CHD events
were ascertained from annual follow-up morbidity and mortality surveillance including
hospitalizations and deaths. Events were reviewed by two physicians and differences
adjudicated. CHD events were defined as non-fatal acute (definitive or probable) MI, fatal
CHD and coronary revascularization procedures (coronary angioplasty or coronary artery
bypass graft) through December 31st, 2005. All subjects provided written informed consent.
CHS is a population-based cohort study of risk factors for CHD and stroke in adults ≥65
years conducted across four field centers in the United States 19. The original predominantly
Caucasian cohort of 5201 persons was recruited in 1989-1990 from a random sample of
people on Medicare eligibility lists and 687 African-Americans were enrolled subsequently
in 1991-1992 for a total sample of 5888. CHS participants completed standardized clinical
examinations and questionnaires at study baseline and 9 annual follow-up visits. Follow-up
for clinical events occurred every 6 months. CHD was classified by the CHS endpoints
committee; suspected events were further investigated by a physician review panel. CHD
events were defined as nonfatal MI, coronary artery angioplasty, coronary bypass surgery, or
CVD death caused by “atherosclerotic CHD”. CHD follow-up was available through June
30, 2007. SHS recruited 4,549 American Indians aged 45 to 74 years from 1989 to 1992
from 13 tribes at three study centers: Oklahoma, North and South Dakota and Arizona 20.
Events were determined from medical records, autopsy reports, and informant interviews; all
materials were independently reviewed by physician members of the SHS study’s morbidity
and mortality committees. CHD events were defined by the occurrence of nonfatal definite
MI, definite CHD, ECG-evident definite MI, fatal definite MI, definite CHD, and sudden
death. Follow-up went from 1989-91 through December 31st, 2006. The Indian Health
Service Institutional Review Board and institutional review boards of the participating
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institutions and participating tribes approved the study; informed consent was obtained from
all participants. WHI is a prospective cohort study investigating post-menopausal women’s
health in the U.S 16. A total of 161, 838 women aged 50–79 years old were recruited from
40 US clinical centers between 1993 and 1998 to participate in the observational study (OS)
and in clinical trials (CT): postmenopausal hormone therapy (estrogen alone or estrogen plus
progestin), a calcium and vitamin D supplement trial, and a dietary modification trial 16.
Study protocols and consent forms were approved by the institutional review boards at all
participating institutions. Annual (OS) and semi-annual (CT) follow-up identifies self-
reported events which are then adjudicated following medical record review 22. CHD was
defined as acute (definitive or probable) MI requiring overnight hospitalization, fatal CHD
or coronary revascularization (coronary angioplasty or coronary artery bypass graft)
procedures. Acute MI was determined according to standardized criteria that included
cardiac pain, cardiac enzyme (and troponin levels) and ECG readings. Events as of August
2009 are included in these analyses. A subset of 21,000 WHI women was selected for
genotyping and for inclusion in the current study. Women were selected based on self-
reported history of disease, incident event outcomes, DNA availability and consent, and
racial/ethnic diversity. Follow-up was through August 2009.
SNP selection and Genotyping
SNPs (in genes or regions) were identified from published GWAS for their association with
CHD and those available as per January 2009 were genotyped in PAGE studies 23-28. SNPs
were available in at least one study for the following loci: the 9p21 region near the
CDKN2A-2B gene (rs1333049, rs2383207, rs10757274), CELSR2/PSRC1/SORT1
(rs599839), SMAD3 (rs17228212), 6p24.1 (rs499818), 16q23.1 (rs2549513), MIA3
(rs17465637), MTHFD1L (rs6922269), 2q36.3 (rs2943634), APOE (rs429358, rs7412),
ZNF627 (rs4804611), CXCL12 (rs501120), LPL (rs268) and PCSK9 (rs11206510). We
examined the correlation among SNPs in the same region using pair-wise r2 and D’
statistics29 for linkage disequilibrium (LD). For three SNPs located in the 9p21 region
(rs10757278, rs1333049, rs2383207) in African Americans (ARIC) and in the American
Indians (SHS), the correlation among SNPs was 0.85 or more in African Americans and in
American Indians (Supplemental Figures 1A-D). Therefore, we only reported associations
for one SNP in the region (rs10757278). For the two APOE SNPs, correlation was 0.99 in all
ethnicities and therefore we reported only associations for rs429358.
Genotyping was performed in two centers: the CALiCo Core Genotyping Laboratory at
Human Genetics Center The University of Texas (Houston, TX) genotyped samples from
ARIC, CHS and SHS using Taqman assays (Applied Biosystems); the Translational
Genomics Research Institute (Phoenix, AZ) genotyped WHI samples using Illumina’s
Veracode GoldenGate genotyping assays. Each laboratory genotyped 360 HapMap samples
for cross-lab and cross-platform quality control. Quality control assessments included
sample call rates (> 95%), concordance of blinded replicates (>98%) and deviation from
Hardy-Weinberg equilibrium among controls within self-reported ethnic group (p<0.01). In
CALiCo populations with prior GWAS characterization (ARIC and CHS), genotyped SNPs
were used (Affymetrix 6.0 for ARIC and Illumina Human 370CNV BeadChip )30. Quality
control for GWAS has been described30. All alleles were aligned to positive strands.
Statistical analysis
All analyses were stratified by study and self-reported ethnicity. Cox proportional hazard
models (implemented in SAS 9.2 using Proc PHREG procedure or in R)31 were used to
estimate ethnic-specific associations of SNPs with CHD (hazard ratios, HR, and 95%
confidence intervals) while adjusting for baseline levels of covariates age and sex, study site
(as applicable) and population stratification. We also performed an analysis adjusting for
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body mass index (BMI), ever smoking, type 2 diabetes, systolic blood pressure, blood
pressure-lowering medication use and education (12 years or equivalent versus less than 12
years). Results were unchanged in fully adjusted models and therefore we report minimally
adjusted models except for 9p21 region in whites. Lipid measures were only available in a
subset of women in the WHI and therefore were not included in analyses. To explore
phenotypic heterogeneity as described by Kitsios et al.32, we also performed sensitivity
analyses using an alternative CHD definition which included only fatal CHD and non-fatal
MI.
PAGE studies used the following strategies to adjust for population stratification: ARIC
whites and WHI used principal components (PC) estimated from pre-existing GWAS data,
adjusting only for PCs significantly associated with the outcome (alpha=0.05). For ARIC
African Americans a set of 1536 ancestry informative markers genotyped among 3965 black
ARIC participants was used to derive mean percentage of European ancestry using the
software ANCESTRYMAP 33. This variable was included as a covariate in the regression
analyses. SHS used self-reported percentage of Indian blood.
All analyses used additive genetic models as described in the initial publications for these
SNPs and/or the replication studies in whites. WHI used weighted analyses to account for
the sampling schema, with sample weights ranging from 1 to 60.4. The study-specific
log(HR) estimates were combined within each ethnicity using inverse-weighted variance
meta-analyses34. Summary estimates and 95% confidence intervals (CI) are reported. A
nominal replication was considered a p-value < 0.05 and a Bonferroni adjusted replication
was considered p-value < 0.0008 (13 SNPs and 5 races for an α=0.05).We also tested for
evidence of between-study heterogeneity 35 by estimating the between-study variance and
the I2 metric, which is a measure of the percentage of the total variation across studies due to
heterogeneity rather than chance 36. For the 9p21 SNP association, which showed significant
between-study heterogeneity (p-value<0.10), we performed stratified analyses by age and
sex.
We also constructed an additive genetic risk score (0-18 alleles) comprising the number of
risk alleles at the nine loci showing significant replication in white individuals (p<0.0008)
using data from the following SNPs (coded allele): rs10757278 (G), rs2549513(A),
rs499818(A), rs6922269(A), rs429358(C), rs4804611(A), rs501120(T), rs268(G) and
rs2943634(C). We then tested the association of categories or continuous risk scores with
incident CHD in WHI, the study that had data on all the SNPs.
For associations in samples of US minorities, we estimated power assuming an additive
genetic effect, magnitude of effect estimate of reported associations in white individuals, an
alpha = 0.05, a two-sided test, and population baseline prevalence of 0.10 (Quanto v.1.2.4).
Results
Associations with incident CHD events were examined in the prospective cohorts of whites
(up to 26,617 individuals and 6,626 events), African Americans (8,018 individuals and 914
events), Hispanics (1,903 individuals and 113 events), American Indians (3,669 individuals
and 595 events) and Asian/Pacific Islanders (885 individuals and 66 events). The mean
follow-up of studies varied from 9.1 to 15.7 person-years (Supplemental Table 1). CHS
participants were older than individuals in other studies and WHI recruited only women
(Table 1). CHD risk factors varied across studies and ethnicities.
We first evaluated replication of SNP associations with incident CHD in samples of white
individuals. Nine of 13 investigated loci associations showed replication by our a priori
criteria (p<0.0008) including the 9p21 region (Table 2), 16q23.1 (rs2549513, p=0.0004),
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6p24.1 (rs499818, p=0.0002), MTHFDIL (rs6922269, p=5.1 × 10−10), 2q26.3 (rs2943634,
p=6.7 × 10−6), APOE (rs429358, p=2.7 × 10−18), ZNF627 (rs4804611, p=5.0 × 10−8),
CXCL12 (rs501120, p=1.4 × 10−6) and LPL (rs268, p=2.7 × 10−17) (Table 3). Meta-analyses
including incident findings from published variants in the ARIC study are shown in
Supplemental Table 2. Replicated loci had similar direction and magnitude of effects as
reported. Using an additive genetic score from these nine SNPs, we observed an increased
hazard of CHD across increasing categories of genetic risk score (Table 5). CELSR2/SORT,
MIA3 and SMAD3 SNPs were not associated with incident events in white individuals.
In the 9p21 region the proxy SNP rs10757278 had associations of similar direction and
magnitude as in published studies, but we noted significant between-study heterogeneity at
this locus (Table 2). Each copy of the rs10757278 G allele was associated with increased
hazard of CHD that varied from 10% (CHS) to 22% (WHI) (p for heterogeneity = 0.03,
I2=71.5%). Study-specific cumulative incidence findings by genotypes are shown in
Supplemental Table 3. Estimates were unchanged in analyses adjusted for multiple CHD
risk factors (Table 2). Sex-specificity and the varying age at recruitment were investigated
as possible sources of the heterogeneity of effects. The hazard ratios for CHD by decade of
age at study recruitment summarized in Figure 1A show a notably greater risk of CHD for
individuals 55 years or younger. The magnitude of the risk estimates decreased with
increasing decade of age, although large heterogeneity remained across age-strata (Figure
1A, Supplemental Table 4). In sex-specific analysis the CHD hazard was greater in women
compared to men, with large between-sex heterogeneity of effects (Figure 1B, Supplemental
Table 5). In analyses stratified by age and sex, the risk of CHD was greater in women than
men at earlier ages (Figure 1C and Supplemental Table 6). To investigate CHD phenotypic
heterogeneity due to inclusion of revascularization procedures, we performed sensitivity
analyses using only non-fatal MI and CHD fatal events. Between-study heterogeneity for the
CHD associations of rs10757278 was no longer present in these analyses (Table 2).
Supplemental Table 7 shows the findings using this definition for additional loci showing
heterogeneity.
We also examined whether SNP associations with CHD generalize to samples of US
minority groups (Tables 4). Because of high correlation between the SNPs in the 9p21
region in African Americans and SHS American Indians (Supplemental Figures 1A-D), we
only report findings for rs10757278. The association of rs10757278 with incident CHD did
not replicate in African Americans despite large sample sizes and greater than 80% power to
detect an effect of similar magnitude to whites (Table 4). SNPs in the 9p21 region were
nominally associated with CHD in American Indians with similar magnitude and direction
of effect as in whites. However, we also observed significant between-study heterogeneity
of effect across the four groups of American Indians, as well as in analyses including only
SHS participants (Table 4). We were unable to evaluate the associations in the 9p21 region
in Hispanics and Asian/Pacific Islander due to limited sample sizes. Other loci showing
nominal associations in minorities are shown in Table 4.
Discussion
Replication of the association of SNPs in the 9p21 region with incident CHD was found in
white individuals, as well as generalization of these associations to American Indians but not
to African Americans, Hispanics or Asian/Pacific Islanders. Our study size was limited for
Hispanics and Asians but prior studies have shown associations of this region with CHD in
Pakistanis (1851 MI cases and 1903 controls) 37, Han Chinese (510 CHD cases and 557
controls) 38, Japanese and Koreans 39, 40 and US Hispanics (82 cases and 108 controls)3.
This locus has been recently shown to disrupt a transcription-factor-biding site involved in
the inflammatory response (STAT1) which affects the expression of the CDKN2A-2B
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genes 41. Consistent with previously reports, we identified age- and sex-specific effects for
the 9p21 locus on CHD risk. The rs10757278 G risk variant showed a larger effect in
younger compared to older cohort participants, more evident for individuals aged 55 years
or younger and in women. Heterogeneity in the estimates for 9p21 in white individuals
persisted even after adjusting for multiple risk factors for CHD, but was no longer present in
analyses that excluded revascularization procedures from the definition of incident CHD
events. Because the use of CHD revascularization procedures (coronary angioplasty or
coronary artery bypass graft) may vary in subgroups of individuals due to indication
(younger symptomatic individuals and men are more likely to be offered procedures) and to
socio-economic factors (access to care), our results highlight the importance of using strict
and homogeneous definition of CHD events when combining data from multiple studies for
evaluation of genetic effects. Thus, our results do not support sex- and age-specific effects
for 9p21 locus for incident CHD.
We were able to replicate multiple other loci in white individuals including MTHFD1L,
16q23.1, 6p24.1, 2q36.3, APOE, ZNF627, CXCL12 and LPL. Most of these loci were
initially identified in the Welcome Trust Case Control Consortium (WTCCC) 24. In general,
we noticed a modestly greater CHD risk in our prospective analysis compared to the
magnitude of association described using a case-control design in prior studies 24, 28, 42.
However, the risk score using these variants showed consistent graded increased CHD risk.
In addition, we found significant between-study heterogeneity for the MTHFD1L and
CXCL12 loci (Supplemental Table 2), similarly to findings recently described in the case-
control meta-analysis of the CARDIoGRAM consortium for the MTHFD1L associations 42.
The direction of effect of the remaining SNPs evaluated in whites was consistent with those
in the discovery studies. Interestingly, three loci, CELSR2/SORT1, MIA3 and PCSK9, which
have been associated with early-onset MI in whites28, did not replicate in our study and in a
recently published study of Finland and Sweden individuals43 . Recent experimental
evidence suggests a role of SORT1 product, sortilin 1, in the hepatic metabolism of
lipoproteins containing apolipoprotein B 44. We had over 80% power to detect an effect for
this locus in whites, assuming effects similar in magnitude to those published. Because our
incident cases were first CHD events occurring after age 45 and the studies that identified
these SNPs were cases of early MI compared to controls, our negative findings are not
inconsistent with the previously reported associations in white individuals.
None of the SNPs tested was significantly associated with CHD in African Americans after
adjustments for multiple testing and our samples in Hispanics and Asians were limited
preventing conclusions. SNPs in the 9p21 region available for this analysis are highly
correlated (r2>0.85) in African Americans. However, the genotyped SNPs may not be ideal
proxy for functional SNPs in the region for populations of recent African ancestry. In
addition, three other well powered SNP associations (rs599839, rs6922269 and rs2943634)
were not significant in African Americans. Testing additional SNPs at these and other loci
may help to elucidate if LD patterns account for some of the negative findings in African
Americans.
The strengths of this study are the prospective evaluation of the genetic effect on CHD risk
in large population based studies and the multi-ethnic evaluation of CHD loci. Our analyses
were limited to SNPs previously identified in individuals of European ancestry, reported by
January 2009, when SNP selection was done for genotyping in PAGE. Therefore, we did not
evaluate recently discovered variants and we were unable to evaluate race-specific variants
in these loci which will require fine mapping of the regions.
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In summary, we identified significant heterogeneity of the 9p21 locus and other loci in
individuals of European ancestry in prospective analyses of CHD risk, some of which could
be explained by differences in event definition. Overall, some SNP associations replicated in
longitudinal analysis of white individuals but effects were modest and none of the SNPs was
associated with incident CHD in large sample sizes of African Americans. Fine-mapping of
these regions may help to clarify these negative findings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Meta-analysis results of the association of rs10757278 9p21 variant by age of study
recruitment (A), sex (B) and age and sex strata (C).
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